Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings

Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, Keiichi Ito, Yota Yasumizu, Ayako Masunaga, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To investigate the prognostic effect of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model reclassification after targeted therapy administration in metastatic renal cell carcinoma (mRCC). Patients and method: A total of 245 mRCC patients treated with targeted therapy are included. The IMDC model reclassification is performed at 1 month after treatment induction of both first-line and second-line targeted therapy. Results: Of the 245 patients, 74 (30.2%) are divided into different risk groups by the IMDC model reclassification after first-line targeted therapy, and patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.018). Of the 119 patients treated with subsequent second-line targeted therapy, 25 (21.0%) are divided into different risk groups by the IMDC model reclassification after second-line targeted therapy, and patients newly classified with poor risk tend to have increased all-cause mortality compared with those remaining in the primary intermediate-risk group (P = 0.007), whereas patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.034). Conclusion: Approximately a quarter of the mRCC patients are classified into different risk groups of the IMDC model following targeted therapy administration in the first-line and second-line settings. There is a significant difference in overall survival of subgroups after the IMDC model reclassifications.

Original languageEnglish
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
Publication statusAccepted/In press - 2015 Oct 22

Fingerprint

Renal Cell Carcinoma
Therapeutics
Survival
Databases
Mortality

Keywords

  • IMDC
  • Metastasis
  • Outcome
  • Prognosis
  • Reclassification
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. / Tanaka, Nobuyuki; Mizuno, Ryuichi; Shirotake, Suguru; Ito, Keiichi; Yasumizu, Yota; Masunaga, Ayako; Ito, Yujiro; Miyazaki, Yasumasa; Hagiwara, Masayuki; Kanao, Kent; Mikami, Shuji; Nakagawa, Ken; Momma, Tetsuo; Masuda, Takeshi; Asano, Tomohiko; Oyama, Masafumi; Oya, Mototsugu.

In: Urologic Oncology: Seminars and Original Investigations, 22.10.2015.

Research output: Contribution to journalArticle

Tanaka, Nobuyuki ; Mizuno, Ryuichi ; Shirotake, Suguru ; Ito, Keiichi ; Yasumizu, Yota ; Masunaga, Ayako ; Ito, Yujiro ; Miyazaki, Yasumasa ; Hagiwara, Masayuki ; Kanao, Kent ; Mikami, Shuji ; Nakagawa, Ken ; Momma, Tetsuo ; Masuda, Takeshi ; Asano, Tomohiko ; Oyama, Masafumi ; Oya, Mototsugu. / Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. In: Urologic Oncology: Seminars and Original Investigations. 2015.
@article{3f9f746025074022aaa3de47de8e7980,
title = "Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings",
abstract = "Purpose: To investigate the prognostic effect of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model reclassification after targeted therapy administration in metastatic renal cell carcinoma (mRCC). Patients and method: A total of 245 mRCC patients treated with targeted therapy are included. The IMDC model reclassification is performed at 1 month after treatment induction of both first-line and second-line targeted therapy. Results: Of the 245 patients, 74 (30.2{\%}) are divided into different risk groups by the IMDC model reclassification after first-line targeted therapy, and patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.018). Of the 119 patients treated with subsequent second-line targeted therapy, 25 (21.0{\%}) are divided into different risk groups by the IMDC model reclassification after second-line targeted therapy, and patients newly classified with poor risk tend to have increased all-cause mortality compared with those remaining in the primary intermediate-risk group (P = 0.007), whereas patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.034). Conclusion: Approximately a quarter of the mRCC patients are classified into different risk groups of the IMDC model following targeted therapy administration in the first-line and second-line settings. There is a significant difference in overall survival of subgroups after the IMDC model reclassifications.",
keywords = "IMDC, Metastasis, Outcome, Prognosis, Reclassification, Renal cell carcinoma, Targeted therapy",
author = "Nobuyuki Tanaka and Ryuichi Mizuno and Suguru Shirotake and Keiichi Ito and Yota Yasumizu and Ayako Masunaga and Yujiro Ito and Yasumasa Miyazaki and Masayuki Hagiwara and Kent Kanao and Shuji Mikami and Ken Nakagawa and Tetsuo Momma and Takeshi Masuda and Tomohiko Asano and Masafumi Oyama and Mototsugu Oya",
year = "2015",
month = "10",
day = "22",
doi = "10.1016/j.urolonc.2016.02.023",
language = "English",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings

AU - Tanaka, Nobuyuki

AU - Mizuno, Ryuichi

AU - Shirotake, Suguru

AU - Ito, Keiichi

AU - Yasumizu, Yota

AU - Masunaga, Ayako

AU - Ito, Yujiro

AU - Miyazaki, Yasumasa

AU - Hagiwara, Masayuki

AU - Kanao, Kent

AU - Mikami, Shuji

AU - Nakagawa, Ken

AU - Momma, Tetsuo

AU - Masuda, Takeshi

AU - Asano, Tomohiko

AU - Oyama, Masafumi

AU - Oya, Mototsugu

PY - 2015/10/22

Y1 - 2015/10/22

N2 - Purpose: To investigate the prognostic effect of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model reclassification after targeted therapy administration in metastatic renal cell carcinoma (mRCC). Patients and method: A total of 245 mRCC patients treated with targeted therapy are included. The IMDC model reclassification is performed at 1 month after treatment induction of both first-line and second-line targeted therapy. Results: Of the 245 patients, 74 (30.2%) are divided into different risk groups by the IMDC model reclassification after first-line targeted therapy, and patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.018). Of the 119 patients treated with subsequent second-line targeted therapy, 25 (21.0%) are divided into different risk groups by the IMDC model reclassification after second-line targeted therapy, and patients newly classified with poor risk tend to have increased all-cause mortality compared with those remaining in the primary intermediate-risk group (P = 0.007), whereas patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.034). Conclusion: Approximately a quarter of the mRCC patients are classified into different risk groups of the IMDC model following targeted therapy administration in the first-line and second-line settings. There is a significant difference in overall survival of subgroups after the IMDC model reclassifications.

AB - Purpose: To investigate the prognostic effect of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model reclassification after targeted therapy administration in metastatic renal cell carcinoma (mRCC). Patients and method: A total of 245 mRCC patients treated with targeted therapy are included. The IMDC model reclassification is performed at 1 month after treatment induction of both first-line and second-line targeted therapy. Results: Of the 245 patients, 74 (30.2%) are divided into different risk groups by the IMDC model reclassification after first-line targeted therapy, and patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.018). Of the 119 patients treated with subsequent second-line targeted therapy, 25 (21.0%) are divided into different risk groups by the IMDC model reclassification after second-line targeted therapy, and patients newly classified with poor risk tend to have increased all-cause mortality compared with those remaining in the primary intermediate-risk group (P = 0.007), whereas patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.034). Conclusion: Approximately a quarter of the mRCC patients are classified into different risk groups of the IMDC model following targeted therapy administration in the first-line and second-line settings. There is a significant difference in overall survival of subgroups after the IMDC model reclassifications.

KW - IMDC

KW - Metastasis

KW - Outcome

KW - Prognosis

KW - Reclassification

KW - Renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84961918313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961918313&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.02.023

DO - 10.1016/j.urolonc.2016.02.023

M3 - Article

C2 - 27040380

AN - SCOPUS:84961918313

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

ER -